Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study…
– New Exploratory Findings from 18-Month Analysis of HELIOS-A Suggest that Treatment with Investigational Vutrisiran May Benefit Patients with…